Physician profile
Christopher Ward
NPI 1235151739
$3,634.40
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $209 · 2021: $594 · 2022: $369 · 2023: $829 · 2024: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297 · Education: $12.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.70 |
| Education | $12.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $721.83 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $363.25 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $289.82 | 2019-2024 | |
| Amgen INC. | $254.00 | 2019-2022 | |
| Abbott Laboratories | $217.94 | 2022-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $205.26 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $182.60 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $168.54 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Esperion Therapeutics, INC. | $123.60 | 2021 | |
| Glaxosmithkline, LLC. | $120.63 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $119.00 | 2023 | Dexcom G7 Gss (161) |
| Janssen Pharmaceuticals, INC | $105.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $90.74 | 2020-2023 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.97 | 2019-2024 | Tradjenta, Jardiance |
| Ironshore Pharmaceuticals INC. | $57.86 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.